文献速递浆细胞疾病

多发性骨髓瘤双特异性抗体治疗后应启动免疫球蛋白预防,无论IgG水平如何

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels.
PubMed 文献 · Blood Adv · 2025-01-01

本文为观点性文章,讨论多发性骨髓瘤患者接受双特异性抗体(如teclistamab、elranatamab、linvoseltamab、talquetamab)治疗后,应启动原发性免疫球蛋白替代治疗(IgRT,即无论IgG水平如何均启动)还是抢先性IgRT(仅当IgG低于某一阈值时启动)。作者基于证据论证原发性预防比抢先性IgG指导的IgRT更安全、更简便,并讨论提高IV和SC免疫球蛋白成本效益的策略。

要点

  • 双特异性抗体治疗多发性骨髓瘤疗效显著但感染风险持续存在。
  • 作者基于证据主张原发性IgRT预防(无论IgG水平)优于抢先性IgG指导的IgRT。
  • 基于任意IgG阈值限制IgRT获取在科学和临床上均不合适。

核心结论

  • 鉴于IgRT压倒性地有利的风险获益特征,加之多发性骨髓瘤中IgG测量的固有局限性,基于任意IgG阈值限制接受双特异性抗体治疗的多发性骨髓瘤患者获取IgRT既无科学依据也不临床合适。

研究设计与样本

  • 观点性文章,对比原发性IgRT预防与抢先性IgG指导的IgRT治疗。

主要发现

  • 双特异性抗体(teclistamab、elranatamab、linvoseltamab、talquetamab)在多发性骨髓瘤中疗效显著,但感染风险不随时间消退。
  • 作者基于证据论证原发性预防比抢先性IgG指导的IgRT更安全、更简便。
  • 作者讨论了提高IV和SC免疫球蛋白全球成本效益的策略。

临床怎么用

  • 作者认为,对于接受双特异性抗体治疗的多发性骨髓瘤患者,不应基于任意IgG阈值限制其获取IgRT。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bispecific antibodies (bsAbs), such as teclistamab, elranatamab, linvoseltamab, and talquetamab, have impressive efficacy in multiple myeloma (MM) but come with substantial infectious risks that do not dissipate over time. Immunoglobulin replacement therapy (IgRT), which includes IV and subcutaneous (SC) immunoglobulins, may lower these risks. In this viewpoint, we contrast primary IgRT prophylaxis (initiation regardless of IgG levels) with preemptive IgRT treatment (initiation only once IgG levels fall below a certain threshold) in this setting. We make evidence-based arguments for primary prophylaxis as a safer and simpler approach than preemptive IgG-guided IgRT. We also discuss strategies to improve the cost-effectiveness of IV and SC immunoglobulins across the world. Given the overwhelmingly favorable benefit-risk profile of IgRT, coupled with the limitations inherent to IgG measurements in MM, withholding IgRT access based on arbitrary IgG thresholds is neither scientifically sound nor clinically appropriate for patients with MM who are receiving bsAb therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Banerjee R, Mohan M, Rejeski K, et al. Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels. Blood Adv. 2025. PMID: 40690761. doi:10.1182/bloodadvances.2025016490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。